Clinical Trial Update: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1 study followed by expansion Phase 2 trial of ZG006 in advanced small cell lung cancer and neuroendocrine cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Cancer
• Small Cell Lung Cancer

Drugs mentioned

• ZG006

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Small Cell Lung Cancer, Neuroendocrine Cancer | Phase 1, Phase 2 | Status: RECRUITING